Funding for this research was provided by:
Japan Society for the Promotion of Science (19K09505 and 19K22685)
Japan Agency for Medical Research and Development (JP22ck0106619)
Received: 25 October 2022
Accepted: 8 August 2023
First Online: 11 September 2023
: This study was approved by the Ethics Committee, Kyoto University Graduate School and Faculty of Medicine (approval number: R1461) and in accordance with the guidelines of the Declaration of Helsinki. The study is retrospective cohort study and only anonymized clinical information of patients was collected without interfering with patients’ treatment plans or posing physiological risks to patients. Informed consent was waived by the same Ethics Committee of Kyoto University. Information about this research, including the purpose, is available on the website of Kyoto University Graduate School and Faculty of Medicine and patients are given the opportunity to refuse to participate in this study.
: Not applicable.
: Dr. Arakawa reported grants from Philips, Otsuka, Chugai, Nihon Medi-Physic, Daiichi Sankyo, Stryker, Eisai, Japan Blood Products Organization, Ono Pharmaceutical, Taiho Pharma, Sumitomo Dainippon Pharma, Astellas Pharma, Sanofi; personal fees from Nippon Kayaku, Novocure, UCB Japan, Ono Pharmaceutical, Brainlab, Merck, Chugai, Eisai, Daiichi Sankyo, Carl Zeiss, Nihon Medi-Physic outside the submitted work. All other authors declare that they have no competing interest.
: No portion of this paper has been presented previously.